EPHA4 and neoplasm: Consequently, RNF5 silencing or RNF5 loss suppresses PEL-derived xenograft tumor growth, with increased EphA4 levels and decreased oncogenic KSHV viral gene expression and genomic viral DNA loads, providing a novel therapeutic candidate for KSHV lytic infection and KSHV-positive PEL treatment.